ESR1 and breast carcinoma: To address this gap, we evaluated pCR rates according to sTIL levels and HG in patients with ER + HER2- breast cancer who received NAC, aiming to identify those who may benefit from chemoimmunotherapy and to explore predictive biomarkers.